| Original language | English (US) |
|---|---|
| Pages (from-to) | 28-29 |
| Number of pages | 2 |
| Journal | Nature biotechnology |
| Volume | 39 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2021 |
ASJC Scopus subject areas
- Biotechnology
- Bioengineering
- Applied Microbiology and Biotechnology
- Molecular Medicine
- Biomedical Engineering
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Nature biotechnology, Vol. 39, No. 1, 01.2021, p. 28-29.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Reply to
T2 - EEG-based model and antidepressant response
AU - Wu, Wei
AU - Pizzagall, Diego A.
AU - Trivedi, Madhukar H.
AU - Etkin, Amit
N1 - Funding Information: W.W. receives salary and equity from Alto Neuroscience. Over the past 3 years, D.A.P. received consulting fees from Akili Interactive Labs, BlackThorn Therapeutics, Boehringer Ingelheim, Compass Pathway, Otsuka and Takeda Pharmaceuticals as well as an honorarium from Alkermes. In addition, he has received stock options from BlackThorn Therapeutics. No funding from these entities was used to support the current work, and all views expressed are solely those of the authors. M.H.T. has served as an adviser or consultant for Abbott Laboratories, Abdi Ibrahim, Akzo (Organon Pharmaceuticals), Alkermes, AstraZeneca, Axon Advisors, Bristol-Myers Squibb, Cephalon, Cerecor, CME Institute of Physicians, Concert Pharmaceuticals, Eli Lilly, Evotec, Fabre Kramer Pharmaceuticals, Forest Pharmaceuticals, GlaxoSmithKline, Janssen Global Services, Janssen Pharmaceutica Products, Johnson & Johnson PRD, Libby, Lundbeck, Meade Johnson, MedAvante, Medtronic, Merck, Mitsubishi Tanabe Pharma Development America, Naurex, Neuronetics, Otsuka Pharmaceuticals, Pamlab, Parke-Davis Pharmaceuticals, Pfizer, PgxHealth, Phoenix Marketing Solutions, Rexahn Pharmaceuticals, Ridge Diagnostics, Roche Products, Sepracor, Shire Development, Sierra, SK Life and Science, Sunovion, Takeda, Tal Medical/Puretech Venture, Targacept, Transcept, VantagePoint, Vivus and Wyeth-Ayerst Laboratories; he has received grants or research support from the Agency for Healthcare Research and Quality, Cyberonics, NARSAD, NIDA and NIMH. A.E. receives salary and equity from Alto Neuroscience and options for equity from Mindstrong Health, Akili Interactive Labs and Sizung for unrelated work.
PY - 2021/1
Y1 - 2021/1
UR - http://www.scopus.com/inward/record.url?scp=85097558245&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097558245&partnerID=8YFLogxK
U2 - 10.1038/s41587-020-0738-2
DO - 10.1038/s41587-020-0738-2
M3 - Letter
C2 - 33318653
AN - SCOPUS:85097558245
SN - 0733-222X
VL - 39
SP - 28
EP - 29
JO - Bio/Technology
JF - Bio/Technology
IS - 1
ER -